Assessment of Clotting Factor Concentrates—Pivotal Studies and Long-Term Requirements

Abstract

Assessment of quality in terms of safety and efficacy of clotting factor concentrates (CFCs) is very important for all new therapeutic products. In rare diseases this is often complicated due to small number of trial participants. In hemophilia, an extra complication is the large impact previous treatments have on both the risk on inhibitors and the overall response to bleedings. For new CFCs, safety needs to be evaluated against inhibitor risk whereas efficacy is primarily judged against the most common clinical manifestations of the disease, namely, bleeding into joints and muscles. In this article the challenges are described for hemophilia that recruits patients globally. Recommendations of ISTH are discussed; these propose to substitute the single-arm prelicensure study with a two-stage approach, which considers epidemic and endemic incidence rate, and might increase the feasibility of studying multiple new products in populations with rare disease without compromising the assessment of product safety and efficacy. We also suggest that the annual bleeding rate (ABR) is an unreliable predictor of efficacy. The response to treatment highly depends on the current disease status of every patient participating in a clinical trial. The phenotype of patients with hemophilia is highly influenced by previous treatment history. Patients with severe hemophilia of the same age can demonstrate a different response to treatment.

Keywords

clotting factor concentrate - safety - efficacy - short-term - long-term

• References

• 1 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
• 2 Goudemand J, Rothschild C, Demiguel V , et al; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107 (1) 46-51
• 3 Gouw SC, van der Bom JG, Ljung R , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (3) 231-239
• 4 European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf . Accessed May 21, 2015
• 5 Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: FDA; 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf . Accessed May 21, 2015
• 6 Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR. The Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (5) 876-879
• 7 O'Mahony B, Peyvandi F, Bok A. Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe?. Haemophilia 2014; 20 (4) 455-458
• 8 Iorio A, Marcucci M. Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?. Haemophilia 2009; 15 (4) 900-903
• 9 Peyvandi F, Rosendaal FR, O'Mahony B, Mannuccio Mannucci P. Pediatric requirements in Europe stymie help for hemophilia. Nat Med 2014; 20 (2) 117
• 10 European Medicine Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products; EMEA/CHMP/EWP139391/2004. London, UK: EMA; 2004. http://www.ispor.org/workpaper/emea-hrql-guidance.pdf . Accessed May 21, 2015.
• 11 Valente M, Cortesi PA, Lassandro G , et al. Health economic models in hemophilia A and utility assumptions from a clinician's perspective. Pediatr Blood Cancer 2015; ; [Epub ahead of print]
• 12 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1) 25-32
• 13 van den Berg HM, Fischer K, Mauser-Bunschoten EP , et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112 (3) 561-565
• 14 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
• 15 van den Berg HM, Feldman BM, Fischer K, Blanchette V, Poonnoose P, Srivastava A. Assessments of outcome in haemophilia—what is the added value of QoL tools?. Haemophilia 2015; 21 (4) 430-435
• 16 Ota S, Mclimont M, Carcao MD , et al. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia 2007; 13 (1) 12-20
• 17 Fischer K, Ljung R, Platokouki H , et al. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia 2014; 20 (4) e280-e286
• 18 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
• 19 Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3) (Suppl. 02) 3-6
• 20 Feldman BM, Funk SM, Bergstrom BM , et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63 (2) 223-230
• 21 Hilliard P, Funk S, Zourikian N , et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12 (5) 518-525
• 22 Fischer K, de Kleijn P. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia 2013; 19 (6) 944-950
• 23 World Health Organization. International Classification of Functioning, Disability and Health (ICF). 2nd ed. Geneva, Switzerland: WHO; May 22, 2001. http://www.who.int/classifications/icf/en/ . Accessed May 21, 2015
• 24 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; (149) 153-159
• 25 Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10 (4) 383-389
• 26 Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia 2009; 15 (5) 1168-1171
• 27 Martinoli C, Della Casa Alberighi O, Di Minno G , et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109 (6) 1170-1179
• 28 Fischer K, Steen Carlsson K, Petrini P , et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122 (7) 1129-1136
• 29 Iorio A, Marcucci M, Cheng J , et al. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. Haemophilia 2014; 20 (6) 777-783